MedPath

A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD

Completed
Conditions
Attention Deficit Disorder With Hyperactivity
Registration Number
NCT02811211
Lead Sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Brief Summary

This noninterventional study will assess genomic changes in the metabotropic glutamate receptor (mGluR) network in children and adolescents with ADHD.

Detailed Description

Male and female subjects 6 to 17 years of age with a primary psychiatric diagnosis of ADHD will be enrolled in this study. The subject and his or her parent/guardian must agree to genotyping to determine whether the subject has disruptive mutations within any of the approximately 274 mGluR-network genes, and complete an interview that will include information about the subject's ADHD history, treatment, and co-morbidities.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1894
Inclusion Criteria
  • The subject is male or female ≥6 and ≤17 years of age.
  • The subject has ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition.
  • The subject, his or her legally responsible representative, and investigator agree to complete ADHD history, treatment, and comorbidity electronic case report form (eCRF).
Exclusion Criteria
  • The subject or parent/legal guardian is in the opinion of the investigator mentally or legally incapacitated and unable to provide informed consent/assent for participation in the study.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Presence of mGluR network mutationsAt study enrollment
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

A.I. DuPont Hospital for Children

🇺🇸

Wilmington, Delaware, United States

© Copyright 2025. All Rights Reserved by MedPath